You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
In Cell this week: method to examine DNA methylation patterns, molecular features of lobular breast cancer, and more.
In PNAS this week: genome and transcriptome of the Asian tiger mosquito, TB diversity and virulence in Inuit populations, and more.
The company plans to establish a clinical laboratory to offer its Gensignia miRNA Signature Classifier for Lung Cancer Test, as well as other tests in the future.
Researchers characterized more than 800 breast tumors using whole-exome sequencing, RNA sequencing, miRNA sequencing, and other methods.
In Nature this week: genomic analysis of 200 bird species, and more.
A team of scientists believe that exosomal miRNAs holds promise to be significant biomarkers for Alzheimer's disease.
The company aims to validate two diagnostic algorithms based in part on microRNA biomarkers to identify patients with moderate-to-severe disease.
The findings reveal a new layer of complexity around the role of microRNAs and highlight how race can influence their role in cancer and potentially other diseases.
NIH researchers have uncovered a blood-based microRNA signature that may be able to tell which patients with precursor disease may progress to myeloma.
Under the arrangement, Rosetta would offer physicians the option to have thyroid samples analyzed by FNApath, with indeterminate samples tested with its microRNA assay.
The US Food and Drug Administration is to announce stricter standards for emergency authorizations of SARS-CoV-2 vaccines, reports the Washington Post.
Bloomberg reports the budget of Operation Warp Speed is actually $18 billion, higher than the number typically cited.
The Associated Press reports Johnson & Johnson is starting a late-stage clinical trial of its candidate SARS-CoV-2 vaccine.
In Genome Research this week: genomic analysis reveals role of super-spreaders in SARS-CoV-2, epigenetic drivers of cancer, and more.